Many translated example sentences containing “eritropoyetina recombinante” – English-Spanish dictionary and search engine for English translations. La farmacocinética de la eritropoyetina recombinante humana en pacientes con nefropatía endémica de los Balcanes. The Pharmacokinetics of Recombinant. Efecto del tratamiento con eritropoyetina recombinante humana sobre la necesidad de transfusión sanguínea en los pacientes críticos. Effect of human.
|Published (Last):||10 September 2015|
|PDF File Size:||12.82 Mb|
|ePub File Size:||3.33 Mb|
|Price:||Free* [*Free Regsitration Required]|
The authors declare that they have no conflicts of interest related to the contents of this article.
The values of C max and t max are comparable to those found by other authors, taking into account the above mentioned differences in methodology. Results of laboratory analyses in examined patients CRP: The utilization of rHuEp changed definitively the treatment and the natural history of anemia in patients with chronic renal insufficiency CRIand now is modifying the treatment of anemia of other non-renal patients as anemia of premature, anemia in onco-hematological illnesses, anemia in human immunodeficiency virus HIV infection, and for reduction of allogenic blood transfusions in surgery.
The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Djukanovic Lj, Radovanovic Z. CiteScore measures average citations received per document published.
No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment.
Ciba Foundation Study Group No.
Pharmacokinetics studies were mostly devoted to the pharmacokinetics of diverse ESA administered by different routes, as well as to the pharmacokinetics of ESA in various groups of chronic kidney disease patients and healthy persons. To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer recombiante. Erythropoietin Epo concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite analyzer Siemens Healthcare Diagnostics.
El nivel de EPO en plasma previo a recombjnante dosis se sustrajo de todos los niveles que se obtuvieron tras administrarla. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator C. J Clin Pharmacol Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. The Impact Factor measures the average number of citations received in a particular year eritropiyetina papers published in the journal during the two receding years. SNIP measures contextual citation impact by wighting citations recimbinante on the total number of citations in a subject field.
As previous studies showed that the kidneys contribute to Epo elimination in a very minor fashion 35 and residual kidney function in patients more than three years on dialysis is most often negligible, it is not expected that renal elimination of Epo could be of any influence. These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, rritropoyetina evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization.
Delayed massive cerebral fat embolism secondary to severe polytrauma. CiteScore measures average citations received per document published.
The group with other kidney diseases consisted of 8 patients with glomerulonephritis, 3 with hypertensive nephropathy, 2 with reflux nephropathy and 1 with polycystic kidney disease.
Srp arh cel lek ; Population pharmacokinetics of darbepoetin alfa in healthy subjects. Endemic nephropathy in Bosnia. Si continua navegando, consideramos que acepta su uso. C reactive protein; Epo: Population pharmacokinetics of erythropoietin in critically ill subjects. The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers. Impact of elevated C-reactive protein levels on erythropoiesis stimulating agent ESA dose and responsiveness in hemodialysis patients.
The presented profiles show greater inter-individual variability in Epo concentration but a faster decrease of Epo level during the elimination phase in non-BEN than in BEN patients. A number of pharmacokinetic studies of ESA have been published, but comparison between them is difficult due to numerous methodological differences.
However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated. Kidney Int Suppl ; Are you a health professional able to prescribe or dispense drugs? J Am Soc Nephrol ;5: It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you.
We comply with the Recombinanye standard for trustworthy health information – verify here. Erythropoietin resistance and survival in non-dialysis patients eritropoyetiha stage chronic kidney disease and heart disease.
Nephrol Dial Transplant ; Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Faculty of Pharmacy, University of Belgrade, Serbia. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Endemic nephropathy in Yugoslavia. This work was conducted as a part of projects No and funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia.
The pharmacokinetic parameters of Epo are presented in Table 3.